Immunovant Stock Performance
| IMVT Stock | USD 17.03 0.01 0.06% |
On a scale of 0 to 100, Immunovant holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 1.39, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunovant will likely underperform. Please check Immunovant's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immunovant's current trending patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunovant are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Immunovant unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.07) | Five Day Return (7.92) | Year To Date Return (32.41) | Ten Year Return 71.11 | All Time Return 71.11 |
1 | Acquisition by Susman Robert Graham of 25016 shares of Immunovant subject to Rule 16b-3 | 05/01/2025 |
2 | Is Immunovant, Inc. The Best Stock That Will Bounce Back | 05/09/2025 |
3 | Disposition of 147 shares by Mark Levine of Immunovant at 30.55 subject to Rule 16b-3 | 05/19/2025 |
4 | Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | 05/29/2025 |
5 | Decoding Immunovant Inc A Strategic SWOT Insight | 05/30/2025 |
6 | Immunovant Navigating The Complexities Of The FcRn Landscape - Seeking Alpha | 06/13/2025 |
7 | Immunovant Stock Updated Nasdaq Composite | 06/23/2025 |
8 | Disposition of 1519 shares by Jay Stout of Immunovant at 17.24 subject to Rule 16b-3 | 07/09/2025 |
9 | Immunovant Raised to Hold at The Goldman Sachs Group | 07/11/2025 |
10 | Goldman Sachs Resumes Coverage of Immunovant with a Hold Rating | 07/16/2025 |
11 | IMVT Announces Key Partnership with Morgan Stanley for New Offering IMVT Stock News | 07/24/2025 |
| Begin Period Cash Flow | 635.4 M | |
| Total Cashflows From Investing Activities | -759 K |
Immunovant | Build AI portfolio with Immunovant Stock |
Immunovant Relative Risk vs. Return Landscape
If you would invest 1,542 in Immunovant on April 27, 2025 and sell it today you would earn a total of 160.50 from holding Immunovant or generate 10.41% return on investment over 90 days. Immunovant is currently generating 0.206% in daily expected returns and assumes 3.0521% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Immunovant, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunovant Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovant's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunovant, and traders can use it to determine the average amount a Immunovant's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0675
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMVT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.05 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Immunovant is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunovant by adding it to a well-diversified portfolio.
Immunovant Fundamentals Growth
Immunovant Stock prices reflect investors' perceptions of the future prospects and financial health of Immunovant, and Immunovant fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovant Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 2.42 B | ||||
| Shares Outstanding | 171.07 M | ||||
| Price To Book | 4.43 X | ||||
| EBITDA | (437.78 M) | ||||
| Net Income | (413.84 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 98 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 4.16 X | ||||
| Cash Flow From Operations | (375.87 M) | ||||
| Earnings Per Share | (2.73) X | ||||
| Market Capitalization | 3.13 B | ||||
| Total Asset | 776.22 M | ||||
| Retained Earnings | (1.24 B) | ||||
| Working Capital | 698.89 M | ||||
About Immunovant Performance
Assessing Immunovant's fundamental ratios provides investors with valuable insights into Immunovant's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Immunovant is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.56) | |
| Return On Capital Employed | (0.62) | (0.59) | |
| Return On Assets | (0.53) | (0.56) | |
| Return On Equity | (0.58) | (0.56) |
Things to note about Immunovant performance evaluation
Checking the ongoing alerts about Immunovant for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunovant help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovant had very high historical volatility over the last 90 days | |
| Net Loss for the year was (413.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (375.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Immunovant has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: IMVT Announces Key Partnership with Morgan Stanley for New Offering IMVT Stock News |
- Analyzing Immunovant's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovant's stock is overvalued or undervalued compared to its peers.
- Examining Immunovant's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovant's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovant's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovant's stock. These opinions can provide insight into Immunovant's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.